A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta

Lawrence N; Oger J; Aziz T; Palace J; Vincent A
September 2003
Journal of Neurology, Neurosurgery & Psychiatry;Sep2003, Vol. 74 Issue 9, p1236
Academic Journal
BACKGROUND: Some multiple sclerosis (MS) patients treated with interferon beta (IFN beta) develop antibodies to the drug. Neutralising antibody (NAB) assays for IFN beta are expensive and the clinical relevance of the results has been debated. OBJECTIVE: To establish a cheap, sensitive, and reliable assay for antibodies to (125)I-IFN beta, and to correlate levels of antibodies with clinical response to IFN beta treatment. METHODS: We established a radioimmunoprecipitation assay (RIPA) using (125)I-IFN beta. We tested NAB positive sera, healthy control sera, and serial samples of 33 IFN beta-1b treated MS patients from the Vancouver cohort of the Berlex pivotal trial who had a high incidence of NABs. RESULTS: We found that the RIPA was highly sensitive for the detection of antibodies to IFN beta-1a and -1b, and that there was a strong correlation between reactivity of NAB positive sera for (125)I-IFN beta-1b and for (125)I-IFN beta-1a. The RIPA was more sensitive and consistent than the NAB. Moreover, there was a trend towards poorer MRI outcomes in RIPA positive patients, but not in NAB-positive patients. CONCLUSIONS: The RIPA assay is sensitive and easy to perform. It should be of value in assessing the clinical impact of IFN beta antibodies, and its use could help target expensive INF beta treatments to those who will respond best.


Related Articles

  • "Neutralizing" Neutralizing Antibodies. de Myer, Desiree // BioPharm International;Jun2003, Vol. 16 Issue 6, p8 

    Discusses the effects of neutralizing antibodies on clinical efficacy of interferon betas which are used as effective therapies for multiple sclerosis. Relapse rate; Increase in disability progression; Multiple factors that can cause the development of antibodies.

  • IFN beta: Neutralizing antibodies.  // Multiple Sclerosis (13524585);Jan99 Supplement 1, Vol. 5 Issue 1, pS91 

    Presents summaries of several studies on interferon β. 'Neutralizing and Binding Anti-IFN- Β Antibodies: A Comparison Between IFN- Β 1a and -1b Treatment in Multiple Sclerosis,' by G. Alm, et al; 'A Study Comparing the Neutralizing Antibodies (Nab's) to Β Interferon in Patients...

  • Serum immunoglobulin levels in MS patients prescribed glatiramer acetate with or without pretreatment with an interferon-β in clinical practice.  // Canadian Journal of Neurological Sciences;May2003 Supplement 2, Vol. 30, pS29 

    Presents an abstract of the study 'Serum Immunoglobulin Levels in MS Patients Prescribed Glatiramer Acetate With or Without Pretreatment With an Interferon-beta in Clinical Practice' submitted to the 38th meeting of the Canadian Congress of Neurological Sciences.

  • A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta. Kob, M; Harvey, J; Schautzer, F; Kascha, S; Bibl, D; Egg, R; Reindl, M; Berger, T; Deisenhammer, F // Multiple Sclerosis (13524585);Feb2003, Vol. 9 Issue 1, p32 

    There is evidence that neutralizing antibodies (NAB) have a negative influence on the clinical and magnetic resonance imaging effects of interferon-beta (IFN�) in multiple sclerosis (MS) patients. The current methods for NAB detection are restricted to specialized laboratories because they...

  • Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox. S�rensen, Per Soelberg // Multiple Sclerosis Journal;Feb2012, Vol. 18 Issue 2, p131 

    The author reflects on the logical paradox of the study on the neutralizing antibodies (NAbs) effects to interferon beta (IFN�) in multiple sclerosis. He states that the effects of IFN� on magnetic resonance imaging (MRI) activity, relapse rate, and progression in Expanded Disability...

  • Interferon-β in der Multiple-Sklerose-Therapie. Hartung, H.-P.; Haas, J.; Meergans, M.; Tracik, F.; Ortler, S. // Der Nervenarzt;Jun2013, Vol. 84 Issue 6, p679 

    The introduction of interferon-β in 1993 in the USA and 2 years later in Europe made it possible for the first time to alter the course of the disease in patients with relapsing-remitting multiple sclerosis (MS). Subsequently, interferon-β was approved for the treatment of patients with...

  • MS Therapy and "late breaking news".  // Multiple Sclerosis (13524585);Sep99 Supplement, Vol. 5, pS18 

    The article presents abstracts of medical research related to multiple sclerosis. They include "Therapy-Induced Anti-Interferon-Beta Antibodies Against Interferon-Beta 1A and Interferon-Beta 1B in Patients With Multiple Sclerosis," "Intravenous Immunoglobulin in Childbirth Related Exacerbation...

  • IFN beta: Neutralizing antibodies.  // Multiple Sclerosis (13524585);Sep99 Supplement, Vol. 5, pS91 

    The article presents abstracts of medical research related to multiple sclerosis. They include "A Study Comparing Neutralizing Antibodies (Nab's) to Beta Interferons in Patients With Multiple Sclerosis," "Neutralising Antibodies in MS Patients Treated With Interferon-1B," and "Autoimmunity...

  • Clinical trials in multiple sclerosis: Current and future requirements — potential pitfalls. Rieckmann, P. // Journal of Neurology;Dec2008 Supplement 6, Vol. 255, p66 

    Several lines of evidence support early immunomodulatory treatment of relapsing multiple sclerosis with either recombinant beta-interferons or glatiramer acetate and positive results from phase III trials encourage start of treatment even in patients with clinical isolated syndrome (CIS)....


Read the Article


Sign out of this library

Other Topics